TITLE

Bioinformatic analyses identifies novel proteincoding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines

AUTHOR(S)
Eng, Lawson; Ibrahim-zada, Irada; Jarjanazi, Hamdi; Savas, Sevtap; Meschian, Mehran; Pritchard, Kathleen I.; Ozcelik, Hilmi
PUB. DATE
January 2011
SOURCE
BMC Medical Genomics;2011, Vol. 4 Issue 1, p18
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Paclitaxel is a microtubule-stabilizing drug that has been commonly used in treating cancer. Due to genetic heterogeneity within patient populations, therapeutic response rates often vary. Here we used the NCI60 panel to identify SNPs associated with paclitaxel sensitivity. Using the panel's GI50 response data available from Developmental Therapeutics Program, cell lines were categorized as either sensitive or resistant. PLINK software was used to perform a genome-wide association analysis of the cellular response to paclitaxel with the panel's SNP-genotype data on the Affymetrix 125 k SNP array. FastSNP software helped predict each SNP's potential impact on their gene product. mRNA expression differences between sensitive and resistant cell lines was examined using data from BioGPS. Using Haploview software, we investigated for haplotypes that were more strongly associated with the cellular response to paclitaxel. Ingenuity Pathway Analysis software helped us understand how our identified genes may alter the cellular response to paclitaxel. Results: 43 SNPs were found significantly associated (FDR < 0.005) with paclitaxel response, with 10 belonging to protein-coding genes (CFTR, ROBO1, PTPRD, BTBD12, DCT, SNTG1, SGCD, LPHN2, GRIK1, ZNF607). SNPs in GRIK1, DCT, SGCD and CFTR were predicted to be intronic enhancers, altering gene expression, while SNPs in ZNF607 and BTBD12 cause conservative missense mutations. mRNA expression analysis supported these findings as GRIK1, DCT, SNTG1, SGCD and CFTR showed significantly (p < 0.05) increased expression among sensitive cell lines. Haplotypes found in GRIK1, SGCD, ROBO1, LPHN2, and PTPRD were more strongly associated with response than their individual SNPs. Conclusions: Our study has taken advantage of available genotypic data and its integration with drug response data obtained from the NCI60 panel. We identified 10 SNPs located within protein-coding genes that were not previously shown to be associated with paclitaxel response. As only five genes showed differential mRNA expression, the remainder would not have been detected solely based on expression data. The identified haplotypes highlight the role of utilizing SNP combinations within genomic loci of interest to improve the risk determination associated with drug response. These genetic variants represent promising biomarkers for predicting paclitaxel response and may play a significant role in the cellular response to paclitaxel.
ACCESSION #
59763101

 

Related Articles

  • Response of Patient-Derived Non-Small Cell Lung Cancer Xenografts to Classical and Targeted Therapies Is Not Related to Multidrug Resistance Markers. Rolff, Jana; Dorn, Cornelia; Merk, Johannes; Fichtner, Iduna // Journal of Oncology;2009, p1 

    Tumor cells that are nonsensitive to anticancer drugs frequently have a multidrug resistant (MDR) phenotype. Many studies with cell lines and patient material have been done to investigate the impact of different resistance markers at protein and mRNA level in drug resistance but with...

  • Recent Developments in the Chemical Biology of Epothilones. Altmann, Karl H. // Current Pharmaceutical Design;May2005, Vol. 11 Issue 13, p1595 

    Epothilones A and B are naturally occurring microtubule-stabilizers, which inhibit the growth of human cancer cells in vitro at nM or even sub-nM concentrations. In contrast to paclitaxel (Taxol�) epothilones are also active against different types of multidrug-resistant cancer cell lines...

  • Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines. Edelman, Martin J.; Quam, Heather; Mullins, Brian; Edelman, M J; Quam, H; Mullins, B // Cancer Chemotherapy & Pharmacology;Aug2001, Vol. 48 Issue 2, p141 

    Purpose: To evaluate in vitro interactions of carboplatin, gemcitabine and paclitaxel in molecularly defined non-small-cell lung cancer lines.Materials and Methods: Three NSCLC lines, A549 (p16-,p53 wt, Rb wt), Calu-1 (p16-, p53-, Rb+) and H596 (p16 wt, p53 mut, Rb-)...

  • Antitumor Effect of Paclitaxel-Loaded PEGylated Immunoliposomes Against Human Breast Cancer Cells. Min-Koo Choi; Fu-De Cui; Seung-Jin Lee; Suk-Jae Chung; Chang-Koo Shim; Dae-Duk Kim // Pharmaceutical Research;Dec2007, Vol. 24 Issue 12, p2402 

    Abstract Purpose  The antitumor effect of paclitaxel-loaded PEGylated immunoliposome (PILs) was investigated in breast cancer cell lines and the xenograft model. Methods  Herceptin was conjugated to paclitaxel-loaded PEGylated liposomes (PLs). In vitro cellular...

  • Differential expression profiling between atypical teratoid/rhabdoid and medulloblastoma tumor in vitro and in vivo using microarray analysis. Hsin-I Ma; Chung-Lan Kao; Yi-Yen Lee; Guang-Yuh Chiou; Lung-Kuo Tai; Kai-Hsi Lu; Chi-Shuan Huang; Yi-Wei Chen; Shih-Hwa Chiou; Ing-Chan Cheng; Tai-Tong Wong // Child's Nervous System;Mar2010, Vol. 26 Issue 3, p293 

    Atypical teratoid/rhabdoid tumor (AT/RT) and medulloblastoma (MB) are the most malignant primary brain tumors in early childhood. AT/RT is frequently misdiagnosed as primitive neuroectodermal tumor/medulloblastoma. The biological features and clinical outcomes of AT/RT and MB are extremely...

  • Synthesis and Antitumor Activity of Novel Pentacyclic Triterpenoid Lantadene D. Sharma, Manu; Dev Sharma, Pritam; Pal Bansal, Mohinder; Singh, Jaswant // Letters in Drug Design & Discovery;Apr2007, Vol. 4 Issue 3, p201 

    Lantadene D was semi-synthetically prepared by functionalizing 22�-hydroxyoleanonic acid and screened for cytotoxicity against four human cancer cell lines (HL-60, HeLa, Colon 502713 and Lung A-549). It was further evaluated for its inhibitory profile against two-stage carcinogenesis in...

  • Rapid Classification of CYP3A4 Inhibition Potential Using Support Vector Machine Approach. Diansong Zhou; Ruifeng Liu; Otmani, Sara A.; Grimm, Scott W.; Zauhar, Randy J.; Zamora, Ismael // Letters in Drug Design & Discovery;Apr2007, Vol. 4 Issue 3, p192 

    The CYP3A4 inhibition SVM classification model achieved high prediction accuracy, which can be used as high throughput computational filter for identifying CYP3A4 inhibition liability. It's demonstrated that the distance to the separating surface in the feature space can be used as valuable...

  • A novel phospholipid gemcitabine conjugate is able to bypass three drug-resistance mechanisms. Alexander, Richard L.; Greene, Bryan T.; Torti, Suzy V.; Kucera, Gregory L. // Cancer Chemotherapy & Pharmacology;Jul2005, Vol. 56 Issue 1, p15 

    We have previously synthesized a phospholipid-gemcitabine conjugate and a phospholipid-cytosine arabinoside conjugate that we tested in different human cancer cell lines. The gemcitabine conjugate was more cytotoxic to the cancer cells tested than the cytosine arabinoside (ara-C) conjugate. The...

  • Low-dose paclitaxel inhibits the induction of epidermal-mesenchymal transition in the human cholangiocarcinoma CCKS-1 cell line. ATSUSHI HIROSE; HIDEHIRO TAJIMA; TETSUO OHTA; TOMOYA TSUKADA; KOICHI OKAMOTO; SHINICHI NAKANUMA; SEISHO SAKAI; JUN KINOSHITA; ISAMU MAKINO; HIROYUKI FURUKAWA; HIRONORI HAYASHI; KEISHI NAKAMURA; KATSUNOBU OYAMA; MASAFUMI INOKUCHI; HISATOSHI NAKAGAWARA; TOMOHARU MIYASHITA; HIROYUKI TAKAMURA; ITASU NINOMIYA; HIROHISA KITAGAWA; SACHIO FUSHIDA // Oncology Letters;2013, Vol. 6 Issue 4, p915 

    Epidermal-mesenchymal transition (EMT) confers an advantage to cancer cells by improving their invasive capacity and metastatic potential. This phenomenon by which epidermal cells change into mesenchymal cells and therefore acquire a higher ability to automaticity, is considered a key process in...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics